^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
aDC1 vaccine
i
Other names: aDC1 vaccine, alphaDC1, alpha-type-1 polarized dendritic cells, autologous alpha-DC1/TBVA vaccine, αDC1-TBVA vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roswell Park, University of Pittsburgh
Drug class:
Immunostimulant
Related drugs:
5ms
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
P2, N=1, Terminated, Roswell Park Cancer Institute | Trial completion date: Apr 2026 --> Jun 2025 | Active, not recruiting --> Terminated; Funding completed
Trial completion date • Trial termination
|
Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
6ms
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (clinicaltrials.gov)
P1/2, N=25, Terminated, Roswell Park Cancer Institute | Trial completion date: Jun 2026 --> Jun 2025 | Suspended --> Terminated | Trial primary completion date: Dec 2025 --> Jun 2025; lack of funding
Trial completion date • Trial termination • Trial primary completion date
|
cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
7ms
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
P2, N=1, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=24 --> 1 | Trial completion date: Nov 2027 --> Apr 2026 | Trial primary completion date: Nov 2027 --> Apr 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
9ms
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2025 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2027
Trial completion date • Trial primary completion date • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
10ms
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=0, Withdrawn, Roswell Park Cancer Institute | N=19 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
12ms
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Oct 2026 --> Feb 2027
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
over1year
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (clinicaltrials.gov)
P1/2, N=25, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting
Enrollment open • Metastases
|
IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CCL2 (Chemokine (C-C motif) ligand 2) • ITGAM (Integrin, alpha M) • FOXP3 (Forkhead Box P3) • CCL22 (C-C Motif Chemokine Ligand 22) • CCL3 (C-C Motif Chemokine Ligand 3) • ITGAX (Integrin Subunit Alpha X)
|
cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
over1year
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2025 --> Nov 2025
Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
over1year
Effects of Injectable Solutions on the Quality of Monocyte-Derived Dendritic Cells for Immunotherapy. (PubMed, J Immunol Res)
Alpha-type-1-polarized dendritic cells (aDC1s) have been shown to induce type-1 immunity with a high capacity to produce interleukin-12p70 (IL-12p70)...Cellular morphology was observed by electron microscopy, and the production of IL-12p70 by aDC1s was evaluated by ELISA. Compared with normal saline, Ringer's lactate solution was more effective at maintaining DC viability for up to 8 hr of incubation at 4 or 22°C.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CSF2 (Colony stimulating factor 2) • IFNA1 (Interferon Alpha 1) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4)
|
aDC1 vaccine
over1year
Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov)
P2, N=42, Recruiting, Jodi Maranchie | Phase classification: P2a --> P2
Phase classification • Combination therapy
|
ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • LAMP3 (Lysosomal Associated Membrane Protein 3) • GZMB (Granzyme B) • BTLA (B And T Lymphocyte Associated) • CD31 (Platelet and endothelial cell adhesion molecule 1) • NRP1 (Neuropilin 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • ANXA5 (Annexin A5)
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine
over1year
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> Aug 2025
Trial completion date • Combination therapy • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
over1year
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: May 2026 --> Oct 2026 | Trial primary completion date: May 2026 --> Oct 2026
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
Share via
